CD274 and non-small cell lung carcinoma: Regarding the combination therapies of PD-1 inhibitors (pembrolizumab or nivolumab) with chemotherapy in 1L setting for patients with NSCLC, there was not a clear association between treatment efficacy with PD-L1 expression [5–7, 10].